Hugel-DexRevo Sign MOU for 'Liquid Polymer Filler'... Full-Scale Launch of New Growth Business

[Asia Economy Reporter Hyunseok Yoo] Hugel is focusing on strengthening its capabilities as a total medical aesthetic company beyond its flagship products, botulinum toxin and HA fillers, through collaboration in the liquid polymer filler business.

Global total medical aesthetic specialist Hugel announced on the 8th that it signed a memorandum of understanding (MOU) with DEXLEVO to promote a new business through exclusive distribution rights of a tissue restoration medical device (hereinafter referred to as liquid polymer filler) mainly composed of PCL (Polycaprolactone, a biodegradable material) at Hugel's Seoul office.

Under this MOU, Hugel secures exclusive domestic sales rights for the liquid polymer filler produced by DEXLEVO and obtains the right of first negotiation for exclusive distribution contracts in overseas regions. The detailed terms of the contract are currently under discussion.

DEXLEVO, established in 2013, is a medical device company specializing in biodegradable polymer-based products. The liquid polymer filler covered by this agreement is the first filler made by applying DEXLEVO's proprietary technology ‘CESABP (Collagenesis-Enabled Solubilized Active Biodegradable Polymer)’, which micronizes PCL into a liquid form.

PCL is a biodegradable material whose safety in the body has been proven through long-term use in medical fields. It has a long duration in the body and excellent collagen production stimulation effects; however, it is known to have a high market entry barrier due to the difficulty of implementing liquid technology that can evenly disperse it within the skin.

Developed based on DEXLEVO’s unique PCL liquefaction technology, this product is expected to provide a continuous collagen production stimulation effect throughout the skin by spreading evenly and decomposing slowly upon injection, unlike existing filler products that help improve deep wrinkles in localized areas.

A DEXLEVO representative stated, “When our liquid polymer filler is injected into the skin, it forms a three-dimensional matrix, which is known to have an anti-aging effect by regenerating collagen reduced due to aging.”

DEXLEVO has completed preparations for entry into the European market by obtaining CE certification for this product this year and is currently conducting a large-scale clinical trial involving 230 patients aiming for domestic release in 2022. Hugel plans to handle exclusive domestic sales of this product after its launch.

Hugel’s flagship botulinum toxin product ‘Botulax’ has strengths in muscle relaxation and reduction, and the HA filler brand ‘The Chaeum’ excels in volume improvement.

The company expects that the liquid polymer filler, which can stimulate collagen regeneration, will enable complementary medical aesthetic procedures alongside these products. Hugel, which rose to first place in the domestic HA filler market in 2019 based on excellent product points and elasticity, plans to become the absolute leader in the domestic filler market estimated at about 200 billion KRW this year through the domestic distribution of the HA filler brand ‘The Chaeum’ and DEXLEVO’s products.

A Hugel representative said, “Following last year’s acquisition of shares in JWorld, a leading company in PDO sutures (lifting threads), and the signing of the business agreement with DEXLEVO, we will leap forward as a global medical aesthetic company with future growth engines. We plan to enhance Hugel’s corporate value in the global market through continuous pipeline expansion and diversification of our business portfolio for existing products.”

This content was produced with the assistance of AI translation services.